CORT
Corcept Therapeutics Incorporated
NASDAQ: CORT · HEALTHCARE · BIOTECHNOLOGY
$51.20
-3.03% today
Updated 2026-06-05
Market cap
$8.90B
P/E ratio
236.89
P/S ratio
11.57x
EPS (TTM)
$0.35
Dividend yield
—
52W range
$29 – $91
Volume
1.2M
Corcept Therapeutics Incorporated (CORT) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed CORT price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$51.20
Today
Analyst consensus
$70.83
+38.34% · 12M
2030 Base
$76.50
+49.41% future
NPV today
$57.22
@ 7% WACC
8 analysts:
5 Buy3 Hold0 Sell
Management guidance
CEO guidance (Q1 2026 earnings, April 30, 2026): FY2026 revenue guidance raised to $950M–$1,050M (midpoint $1,000M), representing 31.3% growth vs. FY2025 actual of $761M. This guidance is driven by FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer (March 2026), strong Korlym prescription trends in Cushing's syndrome, and anticipated return to profitability in Q2 2026. No specific guidance provided for 2027–2030, but management indicated robust pipeline in ALS (dazucorilant Phase 2 showing 87% reduction in mortality risk), oncology, and MASH, positioning for sustained growth beyond 2026.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
CORT · Corcept Therapeutics Incorporated · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$44.82
NPV today: $33.53
Base case (2030)
$76.50
NPV today: $57.22
Bull case (2030)
$124.02
NPV today: $92.77
WallStSmart.com
CORT financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.8B | $1.0B | $1.2B | $1.5B | $1.6B | $1.8B |
| Revenue growth | 12.8% | 31.3% | 23.5% | 18.1% | 11.7% | 9.3% |
| Net margin | — | 7.4% | 12.9% | 15.6% | 17.1% | 18.2% |
| EPS | $0.82 | $0.68 | $1.45 | $2.05 | $2.50 | $2.88 |
| Diluted shares | — | 109M | 110M | 111M | 111M | 112M |
| Net debt | — | $-564.86M | $-749.53M | $-967.55M | $-1.21B | $-1.48B |
| P/S multiple | — | 4.0x | 4.0x | 4.0x | 4.0x | 4.0x |
| Implied price (base) | — | $42.06 | $51.90 | $61.48 | $69.27 | $76.50 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $1.8B | $1.8B | $1.8B |
| P/S multiple | 2.0x | 4.0x | 7.0x |
| Diluted shares | 112M | 112M | 112M |
| Net debt | $-1.48B | $-1.48B | $-1.48B |
| Implied P/E † | 16x | 27x | 43x |
| 2030 Price | $44.82 | $76.50 | $124.02 |
| NPV @ 7% | $33.53 | $57.22 | $92.77 |
† Implied P/E: Multiples remain elevated across all three scenarios because CORT is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $76.50 base case
CORT catalysts and risks
Growth catalysts
+ FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer (March 2026) with strong uptake trajectory
+ Phase 2 dazucorilant DAZALS study showing 87% mortality risk reduction in ALS (announced May 2026); potential Phase 3 initiation and regulatory pathway clarity in 2026–2027
+ Korlym revenue growth acceleration in Cushing's syndrome market, driven by expanded awareness and patient diagnosis
+ Phase 3 ROSELLA ovarian cancer trial data presentations (ASCO 2026) supporting Lifyorli label expansion and market penetration
+ Potential expansion of relacorilant to additional cancer indications (MASH, combination therapies) and international approvals
+ Return to profitability and positive operating leverage in H2 2026 as Lifyorli launch costs normalize and revenue scales
Key risks
- Patent litigation with Teva Pharmaceuticals over Korlym exclusivity; generic competition could erode ~50%+ of legacy revenue base if unfavorable ruling stands
- Lifyorli adoption slower than expected due to reimbursement challenges, competition from nab-paclitaxel monotherapy, or safety signals in real-world use
- ALS program (dazucorilant) failed primary functional endpoint in Phase 2; regulatory path to Phase 3 and commercialization timeline unclear; neurology indication is unproven for company
- EPS deterioration in 2026 due to Lifyorli launch costs ($31.8M net loss in Q1 2026); operating margin recovery contingent on revenue scaling faster than OpEx growth
- High valuation (P/E 168x, P/S 8.2x) leaves stock vulnerable to guidance misses or pipeline setbacks; recent insider selling (CEO, CDO) signals caution
- Ovarian cancer TAM is smaller (~$3B–$5B globally) than legacy Cushing's syndrome; Lifyorli peak sales estimate ~$300M–$500M; combination with nab-paclitaxel limits addressable patient population
- Regulatory risk: FDA could require additional safety data on dazucorilant before Phase 3; relacorilant NDA was rejected in 2025 due to efficacy concerns (though Lifyorli was approved for ovarian cancer combination)
Methodology · Corcept Therapeutics Incorporated 2030 stock forecast model
Corcept Therapeutics Incorporated 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 8 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (5% cumulative for CORT by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($-1.48B by 2030) |
| 3. Time value | NPV calculated using 7% WACC (CAPM: beta 0.355) |
| 4. Multiple framework | P/S compresses with scale: bear 2.0x / base 4.0x / bull 7.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
CORT price target FAQ
What is the CORT price target for 2030?
WallStSmart's Corcept Therapeutics Incorporated 2030 base case is $76.50 per share, with a bull case of $124.02 and bear case of $44.82. The NPV of the base case discounted to today at 7% WACC is $57.22.
How is the Corcept Therapeutics Incorporated 2030 stock forecast calculated?
The CORT 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the CORT price target account for dilution?
Corcept Therapeutics Incorporated is projected to grow diluted share count from 107M to 112M by 2030 (a 5% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 5%.
What is the analyst consensus on CORT stock?
8 analysts cover CORT with an average 12-month price target of $70.83. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.